iStent infinite reduces IOP in patients with advanced OAG

Stand-alone iStent infinite trabecular micro-bypass substantially reduced mean diurnal intraocular pressure (IOP) in patients with advanced to refractory open-angle glaucoma (OAG) who had failed prior medical or surgical treatment, according to a study presented at AAO 2021.

In this prospective multicenter investigational device exemption trial, 72 patients with OAG uncontrolled by prior surgical and/or medical therapy, were enrolled. At baseline, mean IOP was 23.4 mmHg; mean medication taken was 3.1; and patients had a mean of 2 prior surgeries.

All patients underwent a 3-stent, standalone trabecular bypass (The iStent infinite; Glaukos) procedure.

At 12 months, there was a meaningful reduction in IOP from baseline, with 76% of patients achieving ≥20% reduction in mean diurnal IOP on the same or fewer medications and ≥50% of patients achieving IOP reduction ≥30% in mean diurnal IOP from baseline.

Participants had a 13% reduction in medication burden at 12 months, from 3.1 medications at baseline to 2.7 at 12 months after surgery.

Reference
Flowers B, et al. Prospective Multicenter Pivotal Trial of iStent Infinite Trabecular Micro-Bypass in Advanced to Refractory Glaucoma. Presented at: AAO 2021.